Phase II study of irinotecan and amrubicin for relapsed non-small-cell lung cancer

Phase II study of irinotecan and amrubicin for relapsed non-small-cell lung cancer - Irinotecan and amrubicin for relapsed non-small-cell lung cance

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000131

Enrollment

Registered

2005-09-12

Start date

2004-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed non-small-cell lung cancer

Interventions

Combination chemotherapy of irinotecan and amrubicin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically and/or cytologically proven NSCLC No prior surgery, chemotherapy, or radiotherapy Age ≤ 75 and ≥20 ECOG performance status 0 or 1 Measurable disease adequate bone marrow, lung, hepatic, and renal function No prior therapy within four weeks Written informed consent

Exclusion criteria

Exclusion criteria: Active concomitant malignancy Active Interstitial pneumonia Massive effusions Unstable angina, recent myocardial infarction Uncontrolled diabetes Severe active infection Other severe complications Pregnant or lactating women Inappropriate condition for this study judged by physicians.

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Adverse events, overall survival, progression-free survival	—

Countries

Japan

Contacts

Public ContactKatsuyuki Hotta

Okayama Lung Cancer Study Group Coordinating Office Department of Respiratory Medicine, Okayama University Hospital

khotta@md.okayama-u.ac.jp086-235-7227

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026